Kuangli Bio-Tech Holdings Co., Ltd.

Kuangli Bio-Tech Holdings Co., Ltd.

TTWSE:6431
15.80
TWD
-0.05
(-0.32%)
-1.95EPS
1.76BMarket Cap

Total Valuation

TWD

As of June 30, 2026, Kuangli Bio-Tech Holdings Co., Ltd. carries a market capitalization of 1.76B, placing it among publicly traded companies globally. Its enterprise value stands at 2.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.76B
Enterprise Value2.05B

Share Statistics

As of June 30, 2026, Kuangli Bio-Tech Holdings Co., Ltd. has 97.40M shares outstanding.

Shares Outstanding97.40M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 4.83, and the price-to-book ratio stands at 3.48.

PS Ratio4.83
PB Ratio3.48
P/TBV Ratio6.72
P/FCF Ratio-6.91
P/OCF Ratio-7.67

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 5.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.05B versus a market cap of 1.76B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.65

Financial Position

As of June 30, 2026, Kuangli Bio-Tech Holdings Co., Ltd. maintains a current ratio of 1.11, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 99.54, indicating elevated leverage, while an interest coverage ratio of -4.60 demonstrates limited ability to service its debt obligations.

Current Ratio1.11
Quick Ratio0.61
Debt / Equity99.54
Debt / EBITDA-7.23
Interest Coverage-4.60

Financial Efficiency

TWD

Over the twelve months ended June 30, 2026, Kuangli Bio-Tech Holdings Co., Ltd. posted a negative return on equity (ROE) of -34.12, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -16.86, reflecting losses generated across the asset base. The company generates approximately 1.18M in revenue per employee across its workforce of 309.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.39 indicates how many times Kuangli Bio-Tech Holdings Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-34.12
Return on Assets (ROA)-16.86
Revenue Per Employee1.18M
Employee Count309.00
Inventory Turnover5.39

Taxes

TWD

Over the twelve months ended June 30, 2026, Kuangli Bio-Tech Holdings Co., Ltd. recorded 7.54M in income tax expense. The company reported a pretax loss of -182.47M and -193.00M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax7.54M

Stock Price Statistics

TWD

As of the close on November 17, 2026, Kuangli Bio-Tech Holdings Co., Ltd.'s stock has declined approximately 2.47% over the past 52 weeks. The 50-day moving average sits at 16.84, while the 200-day moving average is 20.11.

52-Week Price Change-2.47%
50-Day Moving Average16.84
200-Day Moving Average20.11

Income Statement

TWD

Over the twelve months ended June 30, 2026, Kuangli Bio-Tech Holdings Co., Ltd. generated 363.27M in revenue and converted that into -193.00M in net income, yielding earnings per share of -1.95. EBITDA reached -70.40M, while operating income came in at -147.23M.

Revenue363.27M
Gross Profit89.87M
Operating Income-147.23M
Pretax Income-182.47M
Net Income-193.00M
EBITDA-70.40M
EBIT-156.68M
Earnings Per Share (EPS)-1.95

Balance Sheet

TWD

As of June 30, 2026, Kuangli Bio-Tech Holdings Co., Ltd. holds 221.67M in cash and equivalents against 509.04M in total debt, resulting in a net debt position of 134.69M. Total book value stands at 505.41M, with working capital of 39.71M providing operational flexibility.

Cash & Cash Equivalents221.67M
Total Debt509.04M
Net Debt134.69M
Equity (Book Value)505.41M
Book Value Per Share5.19
Working Capital39.71M

Cash Flow

TWD

Kuangli Bio-Tech Holdings Co., Ltd. produced -228.89M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -25.01M in capital expenditures, free cash flow totaled -253.90M - equivalent to -2.61 per share.

Operating Cash Flow-228.89M
Capital Expenditures-25.01M
Free Cash Flow-253.90M
FCF Per Share-2.61

Margins

Over the twelve months ended June 30, 2026, Kuangli Bio-Tech Holdings Co., Ltd. posted a gross margin of 24.74, reflecting its pricing power and cost economics. The operating margin of -40.53 and net profit margin of -53.13 provide insight into operational efficiency.

Gross Margin24.74
Operating Margin-40.53
Pretax Margin-50.23
Profit Margin-53.13
EBITDA Margin-19.38

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -14.47: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.68, meaning Kuangli Bio-Tech Holdings Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-3.68
FCF Yield-14.47

Stock Splits

Kuangli Bio-Tech Holdings Co., Ltd.'s most recent stock split took place on December 10, 2020.

Last Split Date12/10/2020

Scores

As of June 30, 2026, Kuangli Bio-Tech Holdings Co., Ltd. has an Altman Z-Score of 0.47, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.47